The idea that supplemented probiotic bacteria -- '*live microorganisms that, when administered in adequate amounts, confer a health benefit on the host*' ([@bibr44-0004867416686694]: 58) -- could be used as a treatment for major depressive disorder (MDD) was suggested, in modern times, by [@bibr28-0004867416686694]. A key concept behind this review was that nutritional influences on depression are underestimated and some strains of probiotic bacteria may correct underlying biological factors associated with depression. Indeed, probiotic strains have been shown to lower proinflammatory cytokines ([@bibr27-0004867416686694]) and oxidative stress ([@bibr25-0004867416686694]) in humans, both of which are associated with mood disorders ([@bibr4-0004867416686694]; [@bibr16-0004867416686694]; [@bibr46-0004867416686694]). Gut--brain axis research suggests that bacteria in the gastrointestinal (GI) tract also communicate with the central nervous system in the absence of an immune response ([@bibr12-0004867416686694]; [@bibr24-0004867416686694]).

Many papers have explored the links among gut microbes, brain and behaviour (e.g. [@bibr11-0004867416686694]; [@bibr34-0004867416686694]; [@bibr47-0004867416686694]). A number of narrative reviews suggest manipulation of gut microbiota composition (usually via ingestion of probiotic supplements) as an intervention for psychological outcomes (e.g. [@bibr8-0004867416686694]; [@bibr12-0004867416686694]; [@bibr14-0004867416686694]; [@bibr24-0004867416686694]). [@bibr14-0004867416686694] coined the term 'psychobiotics' to describe probiotic bacteria that produces a health benefit in patients with psychiatric illness. However, these reviews rely mainly on evidence from animal studies in which certain probiotic strains have affected emotional behaviour and brain activity (e.g. [@bibr9-0004867416686694]; [@bibr35-0004867416686694]). For example, [@bibr35-0004867416686694] found that *Lactobacillus helveticus* and *Bifidobacterium Longum --* the probiotic strains used in this study -- had beneficial effects on conditioned defensive burying in rats.

[@bibr48-0004867416686694] provided the first demonstration that probiotics affect brain activity in healthy humans using functional magnetic resonance imaging (fMRI). A recent systematic review found that the human research assessing the impact of probiotics on psychological outcomes is limited, and that the few existing human trials assessed the effect of various probiotic strains on mood in healthy samples only ([@bibr41-0004867416686694]). For example, *L. helveticus* and *B. longum* improved mood and anxiety symptoms in a sample of 55 healthy participants over a 30-day intervention period ([@bibr35-0004867416686694]). As all existing trials were in healthy human subjects, the review concluded that trials in populations selected for a level of psychological distress, or with diagnosed clinical psychiatric disorders, were necessary to advance the field ([@bibr41-0004867416686694]).

Since the 2015 review, [@bibr45-0004867416686694] reported that a multispecies probiotic formulation reduced cognitive reactivity to sad mood significantly more than placebo in a healthy sample; however, there was no effect of probiotics on Beck Depression Inventory (BDI) scores in this study. [@bibr1-0004867416686694] reported a group difference in BDI score after supplementation with probiotics or placebo, adjuvant to citalopram, in a sample with diagnosed MDD; however, this result no longer reached significance when controlling for confounders ([@bibr1-0004867416686694]).

The present trial was a randomized controlled trial testing probiotic bacteria as a primary treatment for mood and other psychological outcomes in a sample selected for low mood. Based on the existing evidence from gut--brain axis research, and on models linking mood disorders with inflammation, immune activation and the state of the gut microbiota, the trial was designed to ascertain whether a specific probiotic formulation containing *L. helveticus* and *B. longum --* previously found to improve emotional behaviour in animals and psychological outcomes and humans -- would improve psychological outcomes in our sample.

This study also aimed to examine whether the levels of blood biomarkers would predict or impact treatment response. Given the association between depression and inflammation, and the effects of probiotics on proinflammatory cytokines, we elected to measure a subset of inflammatory markers (interleukin \[IL\]-1β, IL-6 and tumour necrosis factor alpha \[TNF-α\]). Although this particular probiotic formulation has not been tested for effects on inflammatory markers, several strains of *Lactobacillus* have displayed anti-inflammatory properties *in vitro* in human intestinal epithelial cells ([@bibr50-0004867416686694]), and *B. longum* R0175 has been found to improve symptoms of ulcerative colitis in humans, suggesting potential anti-inflammatory properties ([@bibr21-0004867416686694]). We also measured brain-derived neurotrophic factor (BDNF), as a decrease in inflammation and oxidative stress may lead to increased BDNF, which is a potential factor in the development and maintenance of depression ([@bibr6-0004867416686694]). Emerging evidence suggests that vitamin D is an important modifier of the effects of the intestinal flora on inflammatory processes ([@bibr30-0004867416686694]), which is interesting given the association between vitamin D and low mood ([@bibr2-0004867416686694]), and could be an effect moderator in any interventional research using probiotics for low mood; we therefore measured blood levels of vitamin D. In addition to measuring biomarkers of inflammation, we also aimed to ascertain whether presence, severity or change in irritable bowel syndrome (IBS) symptoms would predict or impact treatment response. There is evidence of high comorbidity of MDD with IBS ([@bibr17-0004867416686694]) suggesting some possible common factors in aetiology, such as an increase in systemic inflammation, which has been observed in both disorders ([@bibr16-0004867416686694]; [@bibr26-0004867416686694]). It was therefore anticipated that symptoms of gut disorder may be an important moderator of treatment response when testing a gut-directed intervention for mood symptoms.

Materials and methods {#section5-0004867416686694}
=====================

Design {#section6-0004867416686694}
------

The trial used a double-blind, randomized, placebo-controlled design, in which participants were assigned (1:1) to receive either the active probiotic or a placebo for 8 weeks. The trial was prospectively registered on the Australian New Zealand Clinical Trials Registry (Ref\#: ACTRN12613000438752; [www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364005&;isReview=true](http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364005&;isReview=true)). No changes were made after trial registration was completed. The study received ethical approval from the national New Zealand Southern Health and Disability Ethics Committee (URA/12/05/013) and the Human Ethics Committee of the University of Canterbury (HEC 2012/67).

Participants {#section7-0004867416686694}
------------

Participants were recruited in Canterbury, New Zealand, via self-referral. Screening was completed using an online survey (<http://bit.ly/UCnutritionresearch>). If a potential participant was ineligible, they were directed to local resources for mental health care. Inclusion criteria were as follows: (1) either ⩾11 on the Quick Inventory of Depressive Symptomatology (QIDS-SR16) or ⩾14 on the depression subscale of the Depression, Anxiety and Stress Scale (DASS-42); (2) aged 16+ at the time of screening; and (3) free of any psychiatric medication for at least 4 weeks prior to the trial. Participants who were currently undergoing regular psychological therapy were allowed to participate and continue with their therapy, provided that they had already been receiving therapy for 6 months or more prior to beginning the trial. Exclusion criteria were as follows: any neurological disorder; renal, hepatic, cardiovascular or respiratory disease; any serious medical condition with major medical interventions anticipated during the trial; pregnancy or breastfeeding; use of any supplement considered potentially antidepressant (e.g. St John's Wort, 5-HTP, SAMe); serious risk of suicide or violence; and current or recent probiotic or antibiotic use. Participants were asked not to consume any other probiotic supplements during the course of the trial. If an antibiotic or antidepressant course was begun by any patient during the course of the trial, then that patient was considered to have violated trial protocol.

Interventions {#section8-0004867416686694}
-------------

The test product was a probiotic formula developed by Lallemand Health Solutions (Mirabel, Quebec, Canada), which contains freeze-dried *L. helveticus* R0052 (strain I-1722 in the French National Collection of Cultures of Microorganisms \[CNCM\], Institut Pasteur, Paris, France) and *B. longum* R0175 (CNCM strain I-3470) bacteria at a dosage of three billion colony-forming units (⩾3 × 10^9^ CFU) per 1.5 g sachet. Excipients used were as follows: xylitol, maltodextrin, plum flavour and malic acid. Bacterial enumeration of the product confirmed that the sachets contained ⩾3 × 10^9^ CFU at the beginning and end of the study. The placebo product contained only the excipients and was sensorially identical to the active product. Both products were room temperature stable and in the form of orally dispersible powder in plain sachets.

Measures {#section9-0004867416686694}
--------

### Demographic information {#section10-0004867416686694}

Date of birth, ethnicity, household income, occupation and highest educational qualification were requested at screening. Occupation data were used to calculate a score of socio-economic status (SES) based on the New Zealand socio-economic index (NZSEI-06) ([@bibr37-0004867416686694]).

### Montgomery--Åsberg Depression Rating Scale {#section11-0004867416686694}

The Montgomery--Åsberg Depression Rating Scale (MADRS) is a well-validated 10-item clinician-rated diagnostic questionnaire designed to measure the severity of depressive episodes ([@bibr38-0004867416686694]). The maximum possible score is 60. Severity cut-offs used were as follows: none/recovered (0--8), mild (9--17), moderate (18--34) and severe (⩾35) ([@bibr39-0004867416686694]); response was defined as \>60% reduction in score from baseline. The patients were rated in person at baseline and 8 weeks.

### Improved Clinical Global Impressions scale {#section12-0004867416686694}

The Improved Clinical Global Impressions (iCGI) scale includes two clinician-rated measures that assess clinical severity on a 7-point scale at the time of rating (severity scale, ICGI-S) and treatment response from baseline on a 13-point scale (improvement scale, iCGI-I) ([@bibr22-0004867416686694]). The patients were rated at baseline and 8 weeks.

### QIDS-SR16 {#section13-0004867416686694}

The QIDS-SR16 is a 16-item self-rated questionnaire designed to assess the severity of depressive symptoms ([@bibr42-0004867416686694]). Scores range from 0 to 27. Severity cut-offs include none (\<6), mild (6--10), moderate (11--15), severe (16--20) and very severe (⩾21). The patients were rated at screening, baseline and every 2 weeks throughout the study.

### Global Assessment of Functioning {#section14-0004867416686694}

The Global Assessment of Functioning (GAF) is a clinician-rated measure on which the social, occupational and psychological functioning of adults is rated from 1--100, with a higher score indicative of better overall functioning ([@bibr10-0004867416686694]). The patients were rated at baseline and 8 weeks.

### DASS-42 {#section15-0004867416686694}

DASS-42 is a 42-item self-report questionnaire designed to assess current severity of symptoms relating to depression, anxiety and stress ([@bibr29-0004867416686694]). The patients were rated at screening, baseline and 8 weeks.

### Irritable Bowel Syndrome Symptom Severity Scale {#section16-0004867416686694}

Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) is a five 100-point sliding scale that assesses the severity and frequency of abdominal pain, the severity of abdominal distention, dissatisfaction with bowel habits and interference with quality of life ([@bibr18-0004867416686694]). Scores range from 0 to 500. Severity cut-offs include remission/no IBS symptoms (\<75), mild (75--175), moderate (175--300) and severe (\>300). The patients were rated at baseline and 8 weeks.

### Biomarkers {#section17-0004867416686694}

Blood samples were collected at baseline and 8 weeks to measure levels of high-sensitivity C-reactive protein (hsCRP), IL-1β, IL-6, TNF-α, vitamin D and BDNF. Testing was completed at Canterbury Health Laboratories. Plasma 25 hydroxycholecalciferol vitamin D was measured using high-performance liquid chromatography (HPLC)-tandem mass spectrometry. HsCRP was measured using latex-enhanced nephelometry. Serum IL-1β, IL-6, TNF-α and BDNF were measured using commercially available enzyme-linked immunosorbent assays (ELISA; R&D Systems). For the hsCRP assays, specimens were collected from patients who had not recently (within the last 4 days) suffered illness or had overt signs of inflammation. HsCRP and vitamin D testing was completed immediately after specimen collection. For the BDNF, IL-1β, IL-6 and TNF-α assays, blood was centrifuged (Eppendorf 5810R centrifuge at 2500 rpm for 10 min) and serum aliquoted immediately after specimen collection and stored at −80°C until batch testing could be completed.

### Monitoring {#section18-0004867416686694}

A checklist of common side effects associated with taking medications (e.g. headaches, rash, nausea) was used every 2 weeks to monitor for adverse events. Participants were also asked to estimate their intake of substances (caffeine, nicotine, alcohol and street drugs) every 2 weeks. Participants were asked every 2 weeks to self-report how many doses of the study product they had taken and missed.

Randomization and blinding {#section19-0004867416686694}
--------------------------

Randomization was completed by a research assistant not otherwise involved in the study: a table of numbers representing probiotic and placebo was randomized (1:1) in blocks of 10 using [www.randomization.com](http://www.randomization.com). Sachets (probiotic and placebo) were pre-packaged according to the randomization code. This meant that participants, clinicians and raters remained blind to the allocated group of each participant until after the database was locked and data analysis was completed.

Study procedure {#section20-0004867416686694}
---------------

Eligible participants attended a meeting at the University of Canterbury conducted by a clinical psychologist, trainee clinical psychologist or a trained research assistant. After informed consent was obtained, clinician-rated measures were rated based on a personal interview. Blood samples were collected, and participants completed self-report questionnaires on a computer-based survey. Participants were allocated to the next sequentially numbered bag. During the 8-week intervention period, participants were asked to take one sachet at the same time each day, preferably before a meal, by pouring the orally dispersible powder from the sachet directly into the mouth where it rapidly dissolved. Participants were monitored every 2 weeks by an online questionnaire. The same procedure was followed at the final assessment.

Sample size {#section21-0004867416686694}
-----------

Due to the lack of any pilot data, the target sample size of 40 per group was selected based on the size of similar studies in the literature and what would identify a clinically meaningful group difference. Randomized controlled trials using probiotics and assessing psychological outcomes typically have a sample size of 40--75 ([@bibr1-0004867416686694]; [@bibr13-0004867416686694]; [@bibr15-0004867416686694]; [@bibr35-0004867416686694]). Recruiting 80 participants in total would be sufficient to show a moderate effect size (\>0.60) for the comparison of probiotic and placebo as statistically significant (two-tail α = 0.05) with 80% power.

Statistical analysis {#section22-0004867416686694}
--------------------

The primary outcome measures defined *a priori* were the MADRS, the iCGI and the QIDS-SR16. IBM SPSS Statistics version 20 was used for all statistical analyses. Baseline variables were compared between treatment groups using t-tests, chi square tests and Mann--Whitney *U* tests. Changes from baseline to the end of treatment were compared using analysis of covariance (ANCOVA), with the baseline level as the covariate. Changes in measures (iCGI-I ratings) were compared using one-way analysis of variance (ANOVA). Efficacy analyses were completed by an independent statistician. The treatment effects were summarized by mean differences and 95% confidence intervals derived from the ANCOVA/ANOVA models. Adverse events occurring in ⩾5% of the sample were compared between groups using Fisher's exact tests. Analyses of all psychological outcome measures were completed on an intention-to-treat basis. The last-observation-carried-forward technique was used to impute missing values. Secondary analyses were undertaken on all psychological outcomes using the per protocol set, defined as those randomized participants who took their allocated product for the full intervention period (⩾80% compliance) and did not violate the study protocol. Biomarker variables were analysed per protocol. Skewed variables were log~10~ transformed. Changes from baseline to the end of treatment were compared using ANCOVA, with the baseline level as the covariate. For log~10~ transformed data, differences derived from the ANCOVA models for each treatment group were back transformed for display as geometric mean ratios, with the ratio of these used for the inter group comparison. Data for non-transformed biomarker variables were summarized by mean differences and 95% confidence intervals derived from the ANCOVA models. All significance tests were two-tailed and p-values \<0.05 were considered statistically significant.

### Exploratory analyses {#section23-0004867416686694}

Hierarchical multiple regression was used to examine whether treatment response was moderated by baseline levels of biomarkers. The baseline value of the dependent variable was entered (with any variable found to be correlated with biomarker levels), followed by experimental group and moderator variable. The interaction between the predictor moderator variable and group was then added into the model as the critical term identifying the presence of a moderating effect. Significant interaction effects were examined by calculating regression slopes one standard deviation above and below the mean of the moderator; simple slope analyses were conducted to examine whether the regression slopes differed significantly from zero.

Results {#section24-0004867416686694}
=======

Study population {#section25-0004867416686694}
----------------

From 203 self-referrals between May 2013 and May 2014, 79 adults (age ⩾ 16 years) with at least moderate low mood completed informed consent and were assigned to the probiotic group (*n* = 40) or placebo group (*n* = 39). Seven people from the probiotic group and three people from the placebo group dropped out prior to finishing the trial (see [Figure 1](#fig1-0004867416686694){ref-type="fig"} for CONSORT diagram), resulting in 10 baseline observations being carried forward for outcome measures rated at baseline and 8 weeks (MADRS, CGI, GAF, DASS-42, IBS-SSS). In addition, 8 mid-trial observations were carried forward on the QIDS-SR16 (taken every 2 weeks throughout the study). Overall, the two groups were well matched in baseline characteristics ([Table 1](#table1-0004867416686694){ref-type="table"}). Six participants were undergoing long-term psychotherapy during the trial: three from the probiotic group and three from the placebo group. No participant discontinued their psychotherapy during the trial. There was a significant imbalance in history of antidepressant usage, with 70% of the probiotic group self-reporting prior antidepressant usage compared with 46% of the placebo group, $\chi_{1}^{2} = 4.617$, *p* \< 0.05. The probiotic group scored significantly higher on the IBS-SSS at baseline (median = 105) than the placebo group (median = 75) (Mann--Whitney *U* test), *U* = 558.5, *Z* = −2.17, *p* \< 0.05. No other significant differences were found.

![CONSORT flow diagram.](10.1177_0004867416686694-fig1){#fig1-0004867416686694}

###### 

Baseline demographic and clinical characteristics of study participants (*n* = 79).

![](10.1177_0004867416686694-table1)

  Characteristic                                                                                                                           Probiotic group (*n* = 40)   Placebo group (*n* = 39)
  ---------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- --------------------------------------------------------------------
  *Demographics*                                                                                                                                                        
   Age, years, mean (SD)                                                                                                                   35.8 (14)                    35.1 (14.5)
   Male, *n* (%)                                                                                                                           8 (20)                       9 (23)
   Socioeconomic status,^[a](#table-fn2-0004867416686694){ref-type="table-fn"}^ mean (SD)                                                  45.0 (11.5)                  41.6 (13.2)
  Education, *n* (%)                                                                                                                                                    
   No high school certificate                                                                                                              3 (8)                        7 (18)
   Completed high school                                                                                                                   13 (33)                      10 (26)
   Post-secondary (e.g. trade certificate)                                                                                                 15 (38)                      13 (33)
   University degree                                                                                                                       9 (23)                       9 (23)
  Ethnic origin, *n* (%)                                                                                                                                                
   New Zealanders of European descent                                                                                                      30 (75)                      31 (80)
   NZ Maori                                                                                                                                2 (5)                        1 (3)
   Other                                                                                                                                   8 (20)                       7 (18)
  *Clinical*                                                                                                                                                            
  Baseline MADRS score, mean (SD)                                                                                                          28.3 (6.1)                   27.0 (6.3)
  Chronic low mood,^[b](#table-fn3-0004867416686694){ref-type="table-fn"},[c](#table-fn4-0004867416686694){ref-type="table-fn"}^ *n* (%)   31 (78)                      24 (62)
  Anxiety disorder,^[c](#table-fn4-0004867416686694){ref-type="table-fn"}^ *n* (%)                                                                                      
   Current                                                                                                                                 20 (50)                      16 (41)
   Past                                                                                                                                    21 (53)                      18 (46)
  Alcohol/substance misuse or dependence,^[c](#table-fn4-0004867416686694){ref-type="table-fn"}^ *n* (%)                                                                
   Current                                                                                                                                 4 (10)                       1 (3)
   Past                                                                                                                                    6 (15)                       8 (21)
  Any co-occurring disorder,^[c](#table-fn4-0004867416686694){ref-type="table-fn"}^ *n* (%)                                                                             
   Current                                                                                                                                 23 (57)                      18 (46)
   Past                                                                                                                                    24 (60)                      21 (54)
  History of antidepressant use,^[c](#table-fn4-0004867416686694){ref-type="table-fn"}^ *n* (%)                                            28 (70)                      18 (46)[\*](#table-fn7-0004867416686694){ref-type="table-fn"}
  Current therapy,^[d](#table-fn5-0004867416686694){ref-type="table-fn"}^ *n* (%)                                                          3 (8)                        3 (8)
  IBS severity,^[e](#table-fn6-0004867416686694){ref-type="table-fn"}^ median (IQR)                                                        105 (53--252)                75 (28--138)[\*](#table-fn7-0004867416686694){ref-type="table-fn"}
  Severity of IBS by category, *n* (%)                                                                                                                                  
   None                                                                                                                                    16 (40)                      19 (49)
   Mild                                                                                                                                    10 (25)                      15 (39)
   Moderate                                                                                                                                8 (20)                       5 (13)
   Severe                                                                                                                                  6 (15)                       0 (0)

MADRS: Montgomery--Åsberg Depression Rating Scale; IBS: irritable bowel syndrome; SD: standard deviation; IQR: interquartile range.

Based on the New Zealand Socio-Economic Index 2006 (NZSEI-06) ([@bibr37-0004867416686694]).

Chronic depression defined as \>2 years continuous symptoms for the current episode of low mood.

Established using self-report and retrospective self-report.

Currently receiving any form of psychotherapy (self-report) -- note that must be regularly for \>6 months in order to meet entry criteria.

Score on Irritable Bowel Syndrome Symptom Severity Scale at baseline (0--500).

Significantly different from probiotic group, *p* \< 0.05.

Psychological efficacy outcomes {#section26-0004867416686694}
-------------------------------

Intent-to-treat analysis (*n* = 79) showed no significant group differences on any outcome measure ([Table 2](#table2-0004867416686694){ref-type="table"}). Secondary analyses based on the per protocol sample (*n* = 69) yielded similar results, with no primary or secondary outcome approaching significance (data not shown). Further analyses controlling for history of antidepressant usage, season at recruitment, and presence/severity of IBS at baseline revealed very similar results to the primary analyses, with no variable tested having a significant effect on any outcome. At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the MADRS (responders), compared to 10 (26%) of those in the placebo group ($\chi_{1}^{2} = 0.107$, *p* = ns).

###### 

Baseline and post 8-week data on psychological outcome measures in intent-to-treat population (*n* = 79).

![](10.1177_0004867416686694-table2)

  Outcome variable                                                 Probiotic     Placebo       Difference \[95% CI\]   *p*           ES^[b](#table-fn10-0004867416686694){ref-type="table-fn"}^ *d*                                         
  ---------------------------------------------------------------- ------------- ------------- ----------------------- ------------- ---------------------------------------------------------------- ------- ---------------------- ------ -------
  MADRS                                                            28.3 (6.1)    19.3 (8.9)    −8.7                    27.0 (6.3)    17.6 (9.5)                                                       −9.7    −1.0 \[−4.9, 3.0\]     0.62   0.11
  iCGI-S                                                           3.8 (0.5)     2.9 (1.1)     −0.9                    3.66 (0.6)    2.7 (1.0)                                                        −0.9    −0.1 \[−0.5, 0.4\]     0.75   0.07
  iCGI-I^[c](#table-fn11-0004867416686694){ref-type="table-fn"}^                 2.4 (2.2)     2.4                                   2.7 (2.0)                                                        2.7     −0.3 \[−1.2, 0.6\]     0.52   0.16
  QIDS-SR16                                                        15.2 (3.9)    8.5 (5.5)     −6.3                    13.2 (3.8)    8.0 (4.8)                                                        −5.6    0.7 \[−1.5, 2.8\]      0.53   0.15
  GAF                                                              61.2 (5.6)    67.5 (8.5)    6.0                     63.1 (5.4)    69.3 (7.1)                                                       6.6     0.7 \[−2.6, 3.9\]      0.68   0.1
  DASS                                                             64.3 (23.9)   37.9 (29.0)   −23.4                   50.0 (20.6)   29.5 (20.8)                                                      −23.6   −0.2 \[−10.6, 10.1\]   0.97   0.01
   *Depression*                                                    24.2 (9.1)    13.2 (11.6)   −9.9                    19.0 (10.5)   10.3 (8.8)                                                       −9.9    −0.03 \[−4.1, 4.1\]    0.99   0.003
   *Anxiety*                                                       15.2 (10.4)   8.9 (9.6)     −5.2                    10.6 (6.6)    6.0 (6.0)                                                        −5.7    −0.4 \[−3.5, 2.6\]     0.78   0.07
   *Stress*                                                        25.0 (9.2)    15.9 (10.4)   −8.1                    20.4 (8.4)    13.2 (8.3)                                                       −8.3    −0.2 \[−4.0, 3.6\]     0.92   0.02

ES: effect size; MADRS: Montgomery--Åsberg Depression Rating Scale; iCGI: improved Clinical Global Impression Scale (Severity/Improvement scale); QIDS-SR16: Quick Inventory of Depressive Symptoms; GAF: Global Assessment of Functioning; DASS: Depression, Anxiety and Stress Scale.

Adjusted for baseline.

Cohen's *d* effect size: measured as the mean difference in change divided by the pooled standard deviation of the change, based on values adjusted for baseline.

Assesses change only, therefore not measured at baseline.

Biomarkers {#section27-0004867416686694}
----------

Baseline blood data were available for 77 participants (probiotic, *n* = 38; placebo, *n* = 39) ([Table 3](#table3-0004867416686694){ref-type="table"}). In total, 58 of the 77 participants (75%) had at least one marker of inflammation (CRP, IL-1β, IL-6 or TNF-α) elevated outside the reference range at baseline (reference ranges shown in [Table 3](#table3-0004867416686694){ref-type="table"}). There were no significant differences in biomarker levels between the active treatment and placebo groups at baseline.

###### 

Baseline biomarker levels for all participants for whom baseline blood data were available (*n* = 77).

![](10.1177_0004867416686694-table3)

  Biomarker                                      Sample with baseline blood data (n = 77)                         
  ---------------------------------------------- ------------------------------------------ ----------- --------- ---------
  CRP (mg/L), reference range: 0--3              1.6                                        0.2--37.3   NA        23 (30)
  IL-1β (pg/mL), reference range: 0--0.201       0.2                                        0--1.7      NA        49 (64)
  IL-6 (pg/mL), reference range: 0.447--9.960    1.9                                        0.4--10.0   2 (3)     3 (4)
  TNF-α (pg/mL), reference range: 0.550--2.816   0.9                                        0.1--3.6    14 (18)   4 (5)
  BDNF (ng/mL), reference range: 6.2--42.6       25.3                                       5.2--48.2   1 (1)     2 (3)
  Vitamin D (nmol/L), reference range: 50--150   52.7                                       11--119     31 (40)   0 (0)

*Abbreviations:* GM = geometric mean; CRP = C-reactive protein; IL = interleukin; TNF = tumor necrosis factor; BDNF = brain derived neurotrophic factor.

Both baseline and end-point blood data were available for 65 participants (probiotic, *n* = 29; placebo, *n* = 36); however, due to some test results falling outside of the range of the assays used, per protocol sets differed for hsCRP (*n* = 55), IL-1β (*n* = 63) and IL-6 (*n* = 62). No significant group differences were observed in change in the level of any biomarker over the intervention period ([Tables 4](#table4-0004867416686694){ref-type="table"} and [5](#table5-0004867416686694){ref-type="table"}). Controlling for time of sample collection had no significant effect on any biomarker outcome.

###### 

Baseline to post 8-week biomarker levels in per protocol population using log~10~ transformed data.

![](10.1177_0004867416686694-table4)

  Biomarker (*n*; active treatment:placebo)   Probiotic   Placebo   GM ratio^[b](#table-fn15-0004867416686694){ref-type="table-fn"}^   *p* ^[c](#table-fn16-0004867416686694){ref-type="table-fn"}^
  ------------------------------------------- ----------- --------- ------------------------------------------------------------------ --------------------------------------------------------------
  CRP (55; 24:31)                             0.83        0.88      0.93 \[0.72, 1.57\]                                                0.75
  IL-1β (63; 27:36)                           0.86        0.85      1.02 \[0.53, 1.82\]                                                0.95
  IL-6 (62; 29:33)                            1.10        0.93      1.20 \[0.66, 1.05\]                                                0.12
  TNF-α (65; 29:36)                           1.09        1.09      1.01 \[0.70, 1.40\]                                                0.96

GML: geometric mean; BL: baseline; CRP: C-reactive protein; IL: interleukin; TNF: tumour necrosis factor; ANCOVA: analysis of covariance.

Post:pre. Based on log~10~ scale; back transformed for display.

Based on log~10~ scale, adjusted for baseline and back transformed.

Significance value derived from the ANCOVA models based on log~10~ scale.

###### 

Baseline to post 8-week biomarker levels in per protocol population.

![](10.1177_0004867416686694-table5)

  Biomarker (*n*; active treatment:placebo)   Probiotic     Placebo       Difference \[95% CI\]   *p*           ES^[b](#table-fn19-0004867416686694){ref-type="table-fn"}^ *d*                                          
  ------------------------------------------- ------------- ------------- ----------------------- ------------- ---------------------------------------------------------------- ------- ----------------------- ------ ------
  Vitamin D, nmol/L (65; 29:36)               57.7 (22.1)   57.1 (21.8)   −1.16                   60.4 (24.3)   57.1 (23.0)                                                      −2.90   1.71 \[−6.79, 10.20\]   0.69   0.10
  BDNF, ng/mL (64; 28:36)                     27.6 (9.0)    27.7 (6.2)    0.95                    25.7 (6.3)    25.6 (8.9)                                                       −0.79   1.75 \[−2.16, 5.66\]    0.38   0.23

SD: standard deviation; BL: baseline; BDNF: brain-derived neurotrophic factor.

Adjusted for baseline.

Cohen's *d* effect size: measured as the mean difference in change divided by the pooled standard deviation of the change, based on values adjusted for baseline.

Monitoring {#section28-0004867416686694}
----------

There were significant group differences in the number of occurrences of two adverse events; however, in both cases, there were more occurrences in the placebo group than the probiotic group (Fisher's exact tests: dry mouth, *p* \< 0.05; sleep disruption, *p* \< 0.05). The rates of all other adverse events did not differ between the groups ([Table 6](#table6-0004867416686694){ref-type="table"}). There were three serious adverse events over the course of the trial, all of which were suicide attempts by one participant from the placebo group. There were no serious adverse events in the probiotic group.

###### 

Treatment-emergent adverse events reported by at least 5% of participants during the trial, by treatment group.

![](10.1177_0004867416686694-table6)

                                  Probiotic group (*n* = 40)   Placebo group (*n* = 39)   *p*
  ------------------------------- ---------------------------- -------------------------- --------------------------------------------------------------
  Constipation                    7                            11                         0.29
  Change in appetite              7                            10                         0.42
  Nausea                          6                            7                          0.77
  Loss of libido                  5                            6                          0.76
  Weight gain                     4                            7                          0.35
  Dry mouth                       2                            8                          0.048[\*](#table-fn20-0004867416686694){ref-type="table-fn"}
  Nightmares                      6                            4                          0.74
  Abdominal pain                  5                            4                          1.00
  Anxiety                         5                            4                          1.00
  Urinary retention               5                            4                          1.00
  Gastrointestinal disturbances   7                            2                          0.15
  Headache                        4                            5                          0.74
  Agitation                       4                            3                          1.00
  Skin rash                       4                            2                          0.68
  Blurred vision                  2                            3                          0.68
  Inability to achieve orgasm     3                            2                          1.00
  Sleep disruption                0                            5                          0.03[\*](#table-fn20-0004867416686694){ref-type="table-fn"}
  Sedation/lethargy               1                            3                          0.36

*p* \< 0.05.

Overall, adherence to the study protocol was good, with 97% of required doses taken as measured by post-study sachet counts. There was no significant difference in compliance rates between groups (number who took a minimum of 95% of required doses; $\chi_{1}^{2} = 0.004$, *p* = ns). During the study period, there were no group differences in rates of alcohol misusers (defined as more than two standard drinks per day for women and three standard drinks per day for men; *n* = 4 \[10%\] for probiotic group, *n* = 2 \[5%\] for placebo group; *p* = ns), smokers (*n* = 8 \[20%\] for probiotic group, *n* = 10 \[35%\] for placebo group; *p* = ns) or cannabis users (*n* = 6 \[15%\] for probiotic group, *n* = 3 \[10%\] for placebo group; *p* = ns).

Exploratory analyses {#section29-0004867416686694}
--------------------

We examined baseline biomarker levels as possible moderators of treatment effect to attempt to provide insights in this very new area of research. Two participants were excluded from the analyses as they did not provide baseline blood data. Significant interaction effects were found between vitamin D and group on several outcome measures. The interaction between group and vitamin D explained significant amounts of variance in iCGI-S (Δ*R*^2^ = 0.07, *p* \< 0.05), QIDS-SR16 (Δ*R*^2^ = 0.05, *p* \< 0.05) and GAF (Δ*R*^2^ = 0.06, *p* \< 0.05) scores over and above the baseline value of the dependent variable, season at time of recruitment (control variable), and the main effects of group and vitamin D. Simple slope analyses revealed that the association between baseline vitamin D and change on these measures was significant for the probiotic group (iCGI-S, *b* = 0.017, *t* = 2.26, *p* \< .05; QIDS-SR16, *b* = 0.082, *t* = 2.60, *p* \< 0.05; GAF, *b* = −0.124, *t* = 2.66, *p* \< 0.05) but not for the placebo group (iCGI-S, *b* = −0.005, *t* = 0.76, *p* = ns; QIDS-SR16, *b* = −0.002, *t* = 0.07, *p* = ns; GAF, *b* = 0.022, *t* = 0.47, *p* = ns). Among those randomized to the probiotic group, those who had high vitamin D at baseline showed greater improvement in mood and functioning than those who had low vitamin D at baseline.

Discussion {#section30-0004867416686694}
==========

Existing evidence suggests that depression is associated with increased permeability of the gut wall ([@bibr32-0004867416686694]), increased immune and inflammatory activation ([@bibr7-0004867416686694]; [@bibr31-0004867416686694]) and gut disorders such as IBS ([@bibr17-0004867416686694]). These underlying biological factors support a proposal made by [@bibr28-0004867416686694] that probiotics could be used as a treatment for depression. This study aimed to undertake preliminary testing of probiotics as a treatment for low mood. The lack of effect of probiotics on psychological outcomes in the present study is perhaps not surprising given the incipient nature of this area of research. There are many possible reasons for the lack of effect; some signals from our exploratory analyses may help to break some ground in this field.

First, it is possible that the findings of this study are restricted by the length of the intervention period or sample size. To our knowledge, the only previous trial to have assessed mood outcomes after probiotic administration in a symptomatic sample is a trial by [@bibr1-0004867416686694], which reported positive effects of probiotics on BDI scores compared with placebo (although this effect was attenuated by confounders) in a sample of 40 participants over 8 weeks; however, this trial used probiotics as an adjuvant treatment alongside citalopram. It is possible that probiotics would take longer than 8 weeks to effect changes in mood when used as a primary treatment in a symptomatic sample, as in the present study. Given that most modern antidepressant studies have reported effect sizes of 0.2--0.4 ([@bibr49-0004867416686694]), it is likely that our study was underpowered to detect an effect of probiotics. However, we think it unlikely that the lack of any observable group difference in this study was an issue of power alone, given the remarkably similar change in outcomes in both groups (*p*-value range = 0.52--0.99). To detect a change at this level would have required a sample of thousands, which would have produced a clinically irrelevant result. In addition, a marginally bigger change was observed in the placebo group than the probiotic group on several outcome measures, which also argues against the lack of observed effect being an issue of power alone. We therefore consider that there were probably multiple factors responsible for the lack of observable effect.

The lack of effect on inflammatory markers is somewhat unexpected given the elevated inflammatory profile of our sample, and given the probable anti-inflammatory effects of some probiotics, including some *Lactobacillus* strains and *B. Longum* ([@bibr21-0004867416686694]; [@bibr50-0004867416686694]). It is possible that these tests were underpowered and may have reached significance in a larger sample. In addition, although we controlled for time of sample collection in our analyses, it would have been preferable to collect samples at the same time for each participant.

The severity and chronicity of the current sample is another consideration: mean baseline MADRS score in the present sample was high in the moderate range and almost 70% of the sample reported continuous low mood lasting more than 2 years. It is possible that probiotics may be more effective in shorter term or in less severe low mood. Baseline severity and chronicity were not reported by [@bibr1-0004867416686694], so no comparison can be drawn.

Recruiting participants not currently receiving pharmacological treatment for their low mood was intended to provide insight into the efficacy of probiotics as a primary, rather than adjunctive, treatment for low mood. However, recruiting a sample of unmedicated participants may have increased the overall treatment resistance of the sample, given that a majority of participants had received antidepressant medications prior to the study and still presented with significant, chronic low mood (self-report). There was an imbalance in prior antidepressant usage between the groups (more of the probiotic group had used antidepressants in the past), which may indicate a higher level of treatment resistance among the probiotic group. Although controlling for the group difference in prior antidepressant usage had no effect on outcomes in this study, it is possible that the overall treatment resistance of the sample is not well represented by prior antidepressant use. We did not formally assess treatment resistance; a standardized measure assessing treatment resistance (e.g. Antidepressant Treatment History Form; [@bibr43-0004867416686694]) may have been valuable in interpreting the results of this trial.

Another potential confounder was that we allowed concurrent therapy on condition that the therapy had been ongoing for 6 months. This decision was taken on the basis of dose--response research that suggests that sudden improvements during long-term psychotherapy (more than 15 sessions) are only as likely as spontaneous remission (see [@bibr20-0004867416686694] for a review). Although it is possible that the inclusion of these participants may have skewed our results, we believe this is unlikely given that only 6 participants (8%) were receiving concurrent psychotherapy, and there was an equal number of these participants in each treatment group (any potential effect on study outcomes was randomized out between the treatment groups).

The probiotic formulation used in this trial has shown positive effects on both emotional behaviour in animal studies ([@bibr3-0004867416686694]; [@bibr35-0004867416686694]) and psychological outcomes in a human study ([@bibr36-0004867416686694]). However, despite the existing evidence to support the efficacy of the study product, it remains possible that different strains, more CFU or more strains combined into a single product may be more effective. It is important that the results of the current study are not generalized to all potential probiotic strains.

Our exploratory analyses appear to show a moderating effect of vitamin D on treatment response. In the probiotic group, participants with high levels of vitamin D at the beginning of the study experienced significantly greater improvement on several psychological outcomes over time than those with low vitamin D at baseline. Baseline vitamin D had no effect on responding in the placebo group. Given the modulatory effects of vitamin D on the immune system ([@bibr5-0004867416686694]) and its role in immune cell development and function ([@bibr19-0004867416686694]), it is possible that the vitamin D status of the host could have an effect on the relationship between the gut microbiota and the immune system: low vitamin D could limit response to probiotic treatment as any changes to the microbiome composition would not necessarily be translated to the immune system. Although this mechanism is unsupported by the lack of any significant effect of probiotics on inflammatory markers in the present study, it is possible that measuring markers of cell-mediated immunity may have been more appropriate. However, it is equally possible that there are other mechanisms that we have yet to consider.

The current study assessed whether probiotics affect mood and other psychological outcomes when used as a primary treatment in a sample selected for low mood. This study has several limitations which should be addressed in future research. Measures of body mass index (BMI), body fat percentage, dietary intake and physical activity should be taken in future probiotics studies. The lack of intestinal microbiome analysis is a significant limitation of the current study, as we are unable to determine whether this probiotic formulation colonized effectively. It is possible that the lack of observed effect of probiotics on psychological outcomes is due to the size of the sample, the length of the intervention period, the severity, chronicity or treatment resistance of the sample, or the strains used. It is equally possible that probiotics are more appropriate as an adjuvant treatment for low mood or depression, as suggested by [@bibr28-0004867416686694]. This is supported by the recent positive trial by [@bibr1-0004867416686694] which showed that probiotics were beneficial to patients with MDD adjuvant to citalopram. Preventative trials giving probiotics to those at risk of gut dysbiosis (e.g. those born by caesarean section or bottle fed in infancy), which record any impact on mental health outcomes in later life, may also prove valuable. [@bibr40-0004867416686694] provided probiotics or a placebo for 6 months in infancy and found a group difference in occurrences of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) at 13 years of age. Early exposure to probiotics may also be protective for developing depression; further longitudinal studies are warranted.

In testing probiotics as a primary treatment for low mood, further studies testing different probiotic strains, for longer intervention periods and in different populations (e.g. less severe/chronic low mood, antidepressant-naive) are important next steps in this very new area of research. Despite the lack of any observable effect of probiotics on psychological or biological outcomes in this study, future studies are strongly encouraged, and should take into account the findings of this study in relation to vitamin D, low levels of which could hinder the efficacy of probiotic supplements for low mood. The continued investigation of probiotics as a potential primary or adjuvant treatment for mood is especially important in light of the emerging research suggesting a novel biological aetiology of mood disorders, such as the relationship with inflammatory/immune response and mitochondrial dysfunction (see [@bibr23-0004867416686694] for a review). The treatments outlined in the clinical practice guidelines for mood disorders recently published by the Royal Australian and New Zealand College of Psychiatrists ([@bibr33-0004867416686694]) adhere very much to the conventional model for treatment of mood disorders; this new understanding of the aetiology of mental disorders necessitates a new paradigm for treatment. This area of research is in its infancy and, given the enormous burden of mood disorders on Western societies, the importance of continuing to explore the therapeutic potential of probiotics for low mood should not be underestimated.
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